摘要:
The invention relates to hybrid particle probes, comprising a nanoparticle of gold with a diameter in the range 2 to 30 nm with at least one, preferably 1 to 100 organic probe molecules and at least 10, preferably 10 to 10,000 molecules with luminescent activity, grafted to the surface thereof, by means of gold-sulphur bonds and a method for production thereof.
摘要:
Hybrid nanoparticles including a nanosphere with a mean diameter in the range 2-9 nm, of which at least 90 wt % consists of Ln2O3, where Ln is a rare earth optionally doped with a rare earth or an actinide, or a mixture of rare earths, or else a rare earth/actinide mixture in which at least 50 % of the metal ions are rare-earth ions; a coating around the nanosphere, of which a major part consists of a functionalised polysiloxane, and which has a mean thickness in the range 0.5-10 nm, preferably more than 2 nm but no more than 10 nm; and at least one bioligand grafted by a covalent bond to the polysiloxane coating; and a method for preparing same.
摘要:
The invention relates to a method for producing a single-phase or multiphase powder, optionally in the form of a colloidal suspension of sesquioxide, oxohydroxide, hydroxide or pure rare-earth mixed oxide, while in a mixture or doped, the rare-earth portion representing more than 50 % of the mass of the obtained powder. The invention also relates to essentially spherical powder particles having a mean diameter ranging between 20 and 800 nm and being nanostructured of Ln2O3 and a colloidal suspension.
摘要:
The invention relates to methods for treating tumors. In particular, the invention provides novel use of nanoparticles in combination with ionizing radiations for treating tumors, wherein the combined effect of nanoparticles induces senescence and/or cannibalism of the tumor cells.
摘要:
L'invention concerne une nouvelle utilisation de nanoparticules ultrafines, utiles comme agent diagnostic, thérapeutique ou théranostic, caractérisée par leur mode d'administration par les voies aériennes. L'invention vise également les applications découlant de ce nouveau mode d'administration, notamment pour l'imagerie des poumons, et le diagnostic ou pronostic des pathologies pulmonaires. Dans le domaine thérapeutique, les applications envisagées sont celles d'agents radio-sensibilisants ou radioactifs pour la radiothérapie (et éventuellement la curiethérapie), pour la neutronthérapie, d'agents pour la PDT (photodynamic therapy), notamment pour le traitement des tumeurs du poumon.